Literature DB >> 2674949

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

D L Barnd1, M S Lan, R S Metzgar, O J Finn.   

Abstract

We have previously reported the establishment of cytotoxic T-cell lines from pancreatic cancer patients, by continuously stimulating tumor-draining lymph node cells with allogeneic pancreatic tumor cell lines. After the preliminary characterization of their phenotype and tumor specificity, detailed studies performed with one of the cell lines, W.D., show that it recognizes a specific antigen, a large and heavily glycosylated mucin molecule, expressed on pancreatic and breast tumors and tumor cell lines. Although this recognition appears major histocompatibility complex (MHC)-unrestricted, the antigen receptor used by the cytotoxic T cell is the alpha/beta heterodimer, typically found on MHC-restricted T cells. The target antigen is atypical, however, in its ability to directly bind and activate the T cells in the absence of self MHC, presumably by abundant and regularly repeated antigenic epitopes. These findings are important because they demonstrate a specific T-cell response against a human tumor-associated antigen. In addition to pancreatic and breast tumors, various mucin molecules are known to be produced by other tumors of epithelial cell origin and could be expected to stimulate similar T-cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674949      PMCID: PMC298015          DOI: 10.1073/pnas.86.18.7159

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity.

Authors:  S F Slovin; R D Lackman; S Ferrone; P E Kiely; M J Mastrangelo
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

2.  Long-term culture and characterization of alloreactive T-cell infiltrates from renal needle biopsies.

Authors:  C Miceli; R S Metzgar; M Chedid; F Ward; O J Finn
Journal:  Hum Immunol       Date:  1985-11       Impact factor: 2.850

3.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Reactivity of anti-human milk fat globule antibodies with synthetic peptides.

Authors:  P X Xing; J J Tjandra; K Reynolds; P J McLaughlin; D F Purcell; I F McKenzie
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.

Authors:  A Anichini; G Fossati; G Parmiani
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

7.  Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.

Authors:  R S Metzgar; N Rodriguez; O J Finn; M S Lan; V N Daasch; P D Fernsten; W C Meyers; W F Sindelar; R S Sandler; H F Seigler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

8.  Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies.

Authors:  A E Frankel; D B Ring; F Tringale; S T Hsieh-Ma
Journal:  J Biol Response Mod       Date:  1985-06

9.  Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies.

Authors:  R S Metzgar; M T Gaillard; S J Levine; F L Tuck; E H Bossen; M J Borowitz
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

10.  Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2.

Authors:  M S Lan; O J Finn; P D Fernsten; R S Metzgar
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

View more
  104 in total

1.  Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

3.  Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1.

Authors:  S K Batra; R S Metzgar; A J Worlock; M A Hollingsworth
Journal:  Int J Pancreatol       Date:  1992-12

4.  Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Catherine A Phillips; Mary Townsend; Ramila Philip; Mark J Dobrzanski; Pamela R Lockwood-Cooke; William Robinson
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

5.  MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection.

Authors:  François Van Laethem; Anastasia N Tikhonova; Alfred Singer
Journal:  Trends Immunol       Date:  2012-07-06       Impact factor: 16.687

6.  Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Authors:  Marijo Bilusic; Christopher R Heery; Philip M Arlen; Myrna Rauckhorst; David Apelian; Kwong Y Tsang; Jo A Tucker; Caroline Jochems; Jeffrey Schlom; James L Gulley; Ravi A Madan
Journal:  Cancer Immunol Immunother       Date:  2013-12-07       Impact factor: 6.968

7.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 8.  Biological treatment for liver tumor and new potential biomarkers.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Mitchell S Wachtel; Marjorie Jenkins; Raffaele Ferrari; Everardo Cobos; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 9.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

10.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.